Evaluation of procalcitonin and CRP as sepsis markers in 74 consecutive patients admitted with prolonged febrile neutropenia by Cornillon, Jerome et al.
Evaluation of procalcitonin and CRP as sepsis markers
in 74 consecutive patients admitted with prolonged
febrile neutropenia
Jerome Cornillon, Marie Bouteloup, Claude Lambert
To cite this version:
Jerome Cornillon, Marie Bouteloup, Claude Lambert. Evaluation of procalcitonin and CRP as
sepsis markers in 74 consecutive patients admitted with prolonged febrile neutropenia. Journal
of Infection, WB Saunders, 2011, 63 (1), pp.93-95. <10.1016/j.jinf.2011.05.010>. <emse-
00604229>
HAL Id: emse-00604229
https://hal-emse.ccsd.cnrs.fr/emse-00604229
Submitted on 28 Jun 2011
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
Journal of Infection, 2011, 63(1), 93-95, doi:10.1016/j.jinf.2011.05.010 
 
1 
Evall uatt ii on  off   procall cii tt onii n  and  CRP  as  sepsii s  markers  ii n  74  
consecutt ii ve  patt ii entt s  admii tt tt ed  wii tt h  proll onged  ff ebrii ll e  
neutt ropenii a    
JÉRÔME CORNILLON(1)*, MARIE BOUTELOUP(1), CLAUDE LAMBERT(2) 
(1) Service d’Hématologie Clinique, Institut de Cancérologie de la Loire, 108, Bis Avenue 
Albert Raimond, 42055 St Etienne Cedex 2. 
(2) Ecole Nationale Supérieure des Mines de Saint Etienne, Centre CIS – Axe des Systèmes 
Biologiques - LPMG UMR CNRS 5148, IFR 143 INSERM IFRESIS ; 158 Cours Fauriel  
42023 Saint-Étienne Cedex 2, France 
Keywords:
                                                       
 
Fever ; bacterial infections; marker of inflammation ; PCT; procalcitonin ; CRP ; 
 
Fever is a major event in critically ill patients. Its causes are difficult to identify and among 
them, bacterial infections must be rapidly identified and treated before sepsis reach a life 
threatening stage. CRP is a very sensitive marker of inflammation of whatever causes 
including sepsis. This is particularly crucial in immunocompromised patients. On the other 
hand, PCT has been extensively shown to be strongly and rapidly produced in bacterial 
infections only. Furthermore, PCT decreases very soon after bacterial resolution, and is thus a 
very useful in monitoring adequacy and efficiency of antibiotics. The utility of this marker in 
sever sepsis is now widely admitted. Recently, Limper et al. described biomarkers in 
discriminating infectious from non-infectious fever [1]. In new intensive chemotherapy 
strategies for the treatment of hemopathies as acute leukemia or bone marrow 
transplantation, profound and prolonged neutropenia (>7 days) expose the patients to life 
threatening infections. In these high risk patients, infections are the main causes of fever and 
bacterial origins are particularly life threatening (septic shock, pneumonia, fungal 
infectious…). Immediate empirical broad-spectrum antimicrobial therapy improves the 
survival but is not always optimal and ineffective treatment must be changed as soon as 
possible [2, 3]. A recent review identifies PCT as a valuable tool in early evaluation of 
antibiotherapy efficacy [4]. But this meta analysis also underlined that published data only 
come from small, retrospective and/or heterogeneous study groups and do not bring any 
proof of high standard of evidence. The only conclusive results have shown interest of PCT in 
short term neutropenia. But regarding more particular populations (i.e.: stem cell 
transplantation) no univocal conclusion is possible from the few published studies [5, 6].  
In this study, we intended to evaluate the interest of PCT versus CRP in early evaluation of 
antibiotherapy efficacy. We have analyzed prospectively serum levels of PCT and CRP every 
morning from the entrance into the intensive care unit for predicted adverse outcome. The 
study was performed in the intensive care unit of hematology of the Oncology’s Institute of St-
Etienne between September 2004 and July 2006. The monitoring concerned all consecutive 
patients who started an intensive chemotherapy program that induces prolonged neutropenia 
(>7 days). 74 patients were included. Among them, 44 were treated for leukemia’s induction 
or consolidation with high dose of aracytin and 32 for bone marrow transplantation. PCT was 
measured by immunoluminometric LACE® technique on Kryptor® instrument according to 
manufacturer instructions (Brahms Diagnostica, Berlin, Germany) (normal value<0.5 μg/l; 
detection limit was 0.10 μg/l), CRP was measured by nephelemetrie on BN ProSpec 
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instrument according to manufacturer instructions (Dade Behring, Siemens Germany) 
(reference value is <10 mg/L). 
At admission, the mean granulocyte count was 3200/mm3 (40–16600). Only 9 patients 
presented granulocyte count below 500/mm3. All patients have developped a neutropénia 
and the median duration of neutropenia was 17 days (from 4 to 113). All patients had at least 
one fever episode, for a median duration of 2 days (1–14). Thirty-eight (51%) episodes of fever 
were documented and considered to be related to bacteriema for 16 (22%) patients or local 
infection such as urinary tract (n = 11; 15%), lung (n = 3; 4%), gut (n = 4; 5%), skin (n = 1; 1%) 
and ear or nose (n = 3; 4%). In these cases, bacteria were a Gram-positive 28% or Gram-
negative 19% bacteria and other (4%). coagulase negative Staphylococcus (14.8%) (2 cultures 
were necessary for diagnosis), Streptococcus (12.1%) and Escherichia Coli (9.5%) were the 
most frequent bacteria involved. 
At patient entrance, PCT and CRP levels were respectively 0.13 μg/l (range: 0.02–1.14) and 
22.7 mg/L (range: 3–271). The PCT or CRP levels at the first day of fever were not 
significantly raised compared to the levels at admission and were not significantly different 
between types of infections (Table 1). We did no find any significant cut-off using Roc curve 
analyses predicting the types of infections. Only 15 patients (21%) reached a PCT level above 
0.5 μg/L at first day of fever. In these patients, 12 patients presented documented bacterial 
infections. Majority of these patients presented a second febrile event (91%). At level of 0.5, 
PCT was positive in 38% of bacteriema and in 27% of localized or undocumented bacteria. On 
the other hand, CRP at admission was significantly higher in patients who had serious events 
later (death or transfert in ICU) at entrance (63.7 vs. 16.3, p = .001) Forty percents of the 
patients with CRP higher than 45 mg/l at admission presented serious event later (required 
intensive care with mechanical ventilation and/or eventually death) compared to 8% of the 
patients who had an initial CRP below this threshold. 
Table 1. PCT and CRP levels of patients, correlated with the category in infection (days+1).  
 Undetermined Pulmonary Blood 
Isolation 
Urinary 
Tract 
Gut Skin ENT 
Nb. of 
patients 
36 3 16 11 4 1 3 
PCT 
Median 
(SD) 
0.17  
(8.33) 
0.66 (3.56) 0.23  
(8.5) 
0.15 
(3.34) 
0.25 
(0.09) 
0.15 
(0.06) 
0.19 
(0.06) 
CRP 
Median 
(SD) 
79.4  
(73) 
75  
(67) 
94  
(85) 
69.6 
(61) 
54.9 
(8) 
73.2 
(−) 
30.2 
(−) 
ENT: Ear-Nose-Throat. 
No difference was noted between categories, but pulmonary’s infections are presented more elevated 
level of PCT. 
 
It is the first time to our knowledge, that PCT predictive values have been analyzed in a 
prospective and exhaustive study. Because we have evaluated PCT values every day during 
neutropenia, we could analyze the dynamic of PCT during the very first 24 h of fever in this 
period. Interestingly, we could not find in these patients any significant raise and then any 
significant predictive value of PCT that could help in the guidance of the treatment as it was 
repeatedly reported in sepsis of patients with normal count of neutrophils. The poor rise of 
PCT levels could be related to the neutropenia and subsequently the lack of source and 
production [7]. Furthermore, because the diagnosis was made very early and the probabilistic 
treatment started immediately, it is possible that the PCT induction was killed in the egg, the 
infectious process being rapidly interrupted. This is in accordance with the short duration of 
fever events and previous reports [2]. And, fortunately, we had no real antibiotherapy failure 
that should have let the PCT raising. It is most probable that prophylaxis including gut 
decontamination (non absorbable by colymicin and gentamycin) and Fluconazole could have 
help in limiting the occurrence of serious events. 
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In order to improve the specificity, manufacturer has proposed to use a cut-off at 2.0 ng/mL 
instead of 0.5 ng/ml. This strategy was not relevant in our early treated patients, in 
accordance with Massaro [8] but this remains controversial [9, 10], probably due to the 
heterogeneity of the populations that have been studied. The basic PCT level was never 
significantly raised and the patient had no inflammatory syndrome as shown by low CRP 
levels. In our experience, PCT above 0.5 μg/mL was significantly associated with clearly 
documented bacterial infection (12/15 total patients) with a good positive predictive value 
(80%). However, only 21% of patients were concerned and other fever events could either be 
related to a short-cut bacterial infection or other infectious causes that rapidly resolved with 
or without the help of the treatment. 
Finally, incidentally, our study has shown a negative predictive value of CRP raise at the 
admission of the patient. This can be related to an underlying inflammatory process possibly 
related to the disease or some incidental pathology. This fact could justify more studies to 
identify possible incident pathologies that could cause a high co-morbidity that could be 
treated in order to reduce the risks for these patients. So, at admission, theses patients should 
be managed with great care and we should promptly anticipate any events in neutropenic 
period. 
Thus, our study shows that early treatment of bacterial infection with probabilistic 
antibiotherapy could strongly reduce morbidity of febrile neutropenic patients according to 
the mean duration of the febrile episode and thus limit the PCT of PCT raise that was 
otherwise extensively demonstrated to be correlated to severe sepsis in non neutropenic 
patients. 
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